Avellino

• Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending
  2024-518386-95-02 4 Non small-cell lung cancer
• A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm … Pending
  2024-519087-41-00 5 Breast cancer is the most common form of cancer among women in North A
• PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Li … Pending
  2025-521666-10-01 4 Mantle Cell Lymphoma
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study Recruiting
  2025-523803-31-00 4 2026-04-16 Advanced non-small cell lung cancer (NSCLC)
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• A study of efficacy and safety of ianalumab in previously treated patients with warm autoimmune haemolytic anaemia Recruiting
  2024-510635-21-00 5 2023-05-09 warm autoimmune haemolytic anaemia (wAIHA)
• ROMANCE Recruiting
  2025-521319-38-00 4 2026-03-11 metastatic colorectal cancer
• Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc … Recruiting
  2024-515765-34-00 5 2026-02-04 English First-line extensive-stage small-cell lung cancer (ES-SCLC)
• Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 Recruiting
  2024-519669-23-00 4 2025-09-29 Patients with metastatic colorectal cancer (mCRC) RAS-mutant
• CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met … Recruiting
  2024-519322-20-00 5 2025-07-21 metastatic colorectal cancer
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• Clinical trial with a combination of Rituximab and Golcadomide as first line therapy for older frail patients with Diffuse Large B-cells non … Recruiting
  2023-506206-38-00 4 2025-04-09 Diffuse Large B-cells non-Hodgkin Lymphoma
• “A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive br … Recruiting
  2024-519514-31-00 4 2025-01-31 metastatic triple-negative PD-L1 positive breast cancer
• MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The M … Recruiting
  2024-516841-38-00 4 2025-01-09 recurrent ovarian cancer wild type for germline and somatic BRCA 1 and
• A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type … Recruiting
  2024-519481-44-00 4 2025-01-08 colorectal metastatic cancer
• Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi … Recruiting
  2024-514420-16-00 4 2024-12-18 RAS/BRAF wild-type metastatic colorectal cancer
• MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting
  2024-516839-27-00 4 2024-12-09 BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting
  2023-509551-14-00 5 2024-06-12 Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
• STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C … Recruiting
  2023-505871-63-00 5 2024-04-08 ER+, HER2- metastatic breast cancer following endocrine and CDK 4/6 in
• A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N … Recruiting
  2022-502980-39-00 5 2024-01-25 Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
• Phase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial. Recruiting
  2022-502775-29-01 5 2023-12-14 Early stage Follicular Lymphoma

Showing 1–24 of 63 trials